April 13, 2022
Alcon has introduced its latest dry eye technology, the Systane iLux2 Meibomian Gland Dysfunction (MGD) Thermal Pulsation System.
With new imaging technology to capture infrared photos and HD video of the meibomian glands, Alcon says this all-in-one handheld device allows patients to see the need for treatment and visualize their procedure, and experience results in as little as one week.i.
“Alcon is dedicated to the advancement of medical device technology and providing eyecare professionals (ECPs) with the tools needed to effectively treat their patients,” said Fred Ellis, Vice-President, U.S. Pharmaceutical and Dry Eye, Alcon. “With the Systane iLux2 MGD Thermal Pulsation System, ECPs will be able to further patient trust and confidence because seeing is believing.”
The Systane iLux2 MGD Thermal Pulsation System expands Alcon’s current dry eye treatment offerings and allows practitioners to tailor MGD treatment to the needs of each of their patients in 8-12 minutes.i, ii
The device’s imaging technology allows patients to view both their meibomian glands and treatment through infrared imaging and HD video of the procedure. ECPs can customize heat and compression across each treatment zone.
Other Articles to Explore
Alcon says Systane iLux2 MGD Thermal Pulsation System can help eyecare practitioners “build a strong, trusting relationship with their patients by boosting the credibility of their treatment recommendation through direct visualization of the disease and tracking the disease over time through stored meibomian gland images.”
“Fifty-six percent of MGD patients see four or more eyecare practitioners in search of proper diagnosis and relief.iii This is a prevalent diagnosis in my practice, and it is essential for me to stay on top of the latest treatment options,” said Eric D. Donnenfeld, MD, FAAO, Ophthalmic Consultants of Long Island in New York. “The new Systane iLux2 MGD Thermal Pulsation System gives me the confidence to customize treatments based on my patients’ needs and help them see, understand and value their MGD treatment.”
i. Tauber J, Owen J, Bloomenstein M, Hovanesian J, Bullimore MA. Comparison of the iLux and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial. Clin Ophthalmol. 2020;14:405-418.
ii. Alcon data on file, 2019.
iii. The Dry Eye Problem. Building Your Dry Eye Center of Excellence. Review of Optometric Business supplement. https://www.reviewob.com/building-your-dry-eye-center-of-excellence/. Accessed April 4, 2022.